Literature DB >> 17552035

Relationship of quantitative structure and pharmacokinetics in fluoroquinolone antibacterials.

Die Cheng1, Wei-Ren Xu, Chang-Xiao Liu.   

Abstract

AIM: To study the relationship between quantitative structure and pharmacokinetics (QSPkR) of fluoroquinolone antibacterials.
METHODS: The pharmacokinetic (PK) parameters of oral fluoroquinolones were collected from the literature. These pharmacokinetic data were averaged, 19 compounds were used as the training set, and 3 served as the test set. Genetic function approximation (GFA) module of Cerius(2) software was used in QSPkR analysis.
RESULTS: A small volume and large polarizability and surface area of substituents at C-7 contribute to a large area under the curve (AUC) for fluoroquinolones. Large polarizability and small volume of substituents at N-1 contribute to a long half life elimination.
CONCLUSION: QSPkR models can contribute to some fluoroquinolones antibacterials with excellent pharmacokinetic properties.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17552035      PMCID: PMC4146770          DOI: 10.3748/wjg.v13.i17.2496

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  58 in total

1.  A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose.

Authors:  R Wise; J M Andrews; J P Ashby; J Marshall
Journal:  J Antimicrob Chemother       Date:  1999-11       Impact factor: 5.790

2.  Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.

Authors:  S Lober; S Ziege; M Rau; G Schreiber; A Mignot; P Koeppe; H Lode
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Pharmacokinetics of temafloxacin in humans after single oral doses.

Authors:  G R Granneman; P Carpentier; P J Morrison; A G Pernet
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

4.  Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent.

Authors:  R Wise; J Johnson; N O'Sullivan; J M Andrews; B P Imbimbo
Journal:  J Antimicrob Chemother       Date:  1991-12       Impact factor: 5.790

5.  Safety, tolerability and pharmacokinetics of the new long-acting quinolone DW-116 after single and multiple dosing in healthy subjects.

Authors:  C Meyerhoff; C Dilger; S J Yoon; Y H Chung; D K Lee; C W Lee; J M Ryu; M S Choi; G Pabst; C Reh
Journal:  J Antimicrob Chemother       Date:  1998-09       Impact factor: 5.790

6.  Temafloxacin pharmacokinetics in subjects with normal and impaired renal function.

Authors:  G R Granneman; R Braeckman; J Kraut; S Shupien; J C Craft
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

7.  Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species.

Authors:  H M Siefert; A Domdey-Bette; K Henninger; F Hucke; C Kohlsdorfer; H H Stass
Journal:  J Antimicrob Chemother       Date:  1999-05       Impact factor: 5.790

8.  Antimicrobial activity of Sapindus mukorossi and Rheum emodi extracts against H pylori: In vitro and in vivo studies.

Authors:  Mohammed Ibrahim; Aleem-A Khan; Santosh-K Tiwari; Mohammed-Aejaz Habeeb; M-N Khaja; C-M Habibullah
Journal:  World J Gastroenterol       Date:  2006-11-28       Impact factor: 5.742

9.  Inter- and intrasubject variabilities in the pharmacokinetics of rufloxacin after single oral administration to healthy volunteers.

Authors:  B P Imbimbo; G Broccali; M Cesana; F Crema; G Attardo-Parrinello
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

10.  Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects.

Authors:  H Stass; A Dalhoff; D Kubitza; U Schühly
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.